Page 1

PROKIDNEY Exhibit 99.1 • • • ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis , positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full enrollment for PROACT 1 in the second half of 2026 Appointed Kenneth Locke as Chief Technical Officer , adding more than 25 years of R & D , CMC and supply chain leadership experience Ended Q2 2026 with $ 181.6 million in cash and cash equivalents and marketable securities , supporting operations into mid - 2027 " ProKidney " or the " Company " ) , a CKD ) , today reported WINSTON - SALEM , N.C. , August 10 , 202 - ProKidney Corp Nasdaq : PROK ) ( leading late clinical - stage cell therapy company focused on chronic kidney disease ( financial results for the second quarter ended June 30 , 202 , and provided business highlights . " This update marks an important milestone for ProKidney as we have completed enrollment for the PROACT 1 accelerated approval analysis , positioning us for our pivotal eGFR slope topline readout anticipated in the second quarter of 2027 , " said Bruce Culleton , M.D. , CEO of ProKidney . " We also remain on track to complete full enrollment for PROACT 1 in the second half of this year and recently strengthened our leadership team with the appointment of Ken Locke as Chief Technical Officer , adding deep manufacturing and supply chain e pertise as we prepare for future regulatory and commercial milestones . Our focus remains on advancing rilparencel as a potential new treatment option for patients with advanced CKD and type 2 diabetes who are at high risk of kidney failure , an area of significant unmet medical need . " Business Highlights Phase 3 REGEN - 006 PROACT 1 ) Study • Completed enrollment of patients contributing to the accelerated approval efficacy analysis , which is e imately 320 patients and evaluate annualized imately 470 patients in the second half of 202 eGFR slope as the surrogate endpoint ; topline results are anticipated in Q2 2027 pected to include appro • On track to complete full enrollment of appro for the confirmatory composite time - to - event analysis ; topline results anticipated in the second half of 2029 Leadership Update e In June 202 , ProKidney appointed Kenneth Locke as Chief Technical Officer . Mr. Locke brings more than 25 years of perience across R & D , Chemistry , Manufacturing , and Controls ( CMC ) and Supply Chain . Most recently , he served as Senior Vice President of Technical Operations at Carisma Therapeutics , where he oversaw CMC , Quality , and Regulatory functions and led technical strategy for first - in - human CAR Myeloid programs . Prior to Carisma , he held leadership roles at Celgene ( now Bristol Myers Squibb ) , where he led e manufacturing and strategic sourcing for cell therapy programs , and at Novartis , ternal